INSM Logo

Insmed Inc (INSM) Stock Forecast & Price Prediction

Live INSM Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$78.12

-1.83 (-2.29%)

12 Month Price Forecast For INSM

$78.12
Current Price
$14.30B
Market Cap
17 Ratings
Buy 17
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to INSM Price Forecasts

+34.4%
To High Target of $105.00
+15.2%
To Median Target of $90.00
-13.9%
To Low Target of $67.26

INSM Price Momentum

-3.6%
1 Week Change
+19.7%
1 Month Change
+176.5%
1 Year Change
+13.2%
Year-to-Date Change
-4.8%
From 52W High of $82.04
+256.4%
From 52W Low of $21.92

๐Ÿค” Considering Insmed (INSM)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 3:40 AM UTC

INSM Analyst Ratings & Price Targets

Based on our analysis of 21 Wall Street analysts, INSM has a bullish consensus with a median price target of $90.00 (ranging from $67.26 to $105.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $78.12, the median forecast implies a 15.2% upside. This outlook is supported by 17 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Nicole Germino at Truist Securities, projecting a 34.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

INSM Analyst Consensus

17
Buy
0
Hold
0
Sell

INSM Price Target Range

Low
$67.26
Average
$90.00
High
$105.00
Current: $78.12

Latest INSM Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for INSM.

Date Firm Analyst Rating Change Price Target
Feb 7, 2025 JP Morgan Jessica Fye Overweight Maintains $92.00
Feb 7, 2025 Guggenheim Vamil Divan Buy Maintains $101.00
Feb 6, 2025 Morgan Stanley Matthew Harrison Overweight Maintains $90.00
Nov 22, 2024 JP Morgan Jessica Fye Overweight Maintains $83.00
Nov 1, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $90.00
Nov 1, 2024 Truist Securities Nicole Germino Buy Reiterates $105.00
Oct 11, 2024 Truist Securities Nicole Germino Buy Maintains $100.00
Oct 9, 2024 B of A Securities Jason Zemansky Buy Maintains $86.00
Oct 3, 2024 JP Morgan Jessica Fye Overweight Maintains $74.00
Sep 9, 2024 Cantor Fitzgerald Josh Schimmer Overweight Reiterates $0.00
Aug 29, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $90.00
Aug 12, 2024 Truist Securities Nicole Germino Buy Maintains $85.00
Aug 12, 2024 HC Wainwright & Co. Andrew Fein Buy Reiterates $90.00
Aug 9, 2024 Stifel Stephen Willey Buy Maintains $88.00
Aug 9, 2024 TD Cowen Ritu Baral Buy Maintains $98.00
Aug 9, 2024 UBS Trung Huynh Buy Maintains $84.00
Jul 12, 2024 Morgan Stanley Matthew Harrison Overweight Maintains $85.00
Jul 10, 2024 Goldman Sachs Andrea Tan Buy Maintains $102.00
Jul 9, 2024 Guggenheim Vamil Divan Buy Maintains $95.00
Jul 8, 2024 HC Wainwright & Co. Andrew Fein Buy Maintains $90.00

Stocks Similar to Insmed Inc

The following stocks are similar to Insmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Insmed Inc (INSM) Financial Data

Insmed Inc has a market capitalization of $14.30B with a P/E ratio of -14.7x. The company generates $342.96M in trailing twelve-month revenue with a -252.0% profit margin.

Revenue growth is +18.2% quarter-over-quarter, while maintaining an operating margin of -212.7% and return on equity of -890.7%.

Valuation Metrics

Market Cap $14.30B
Enterprise Value $14.00B
P/E Ratio -14.7x
PEG Ratio -18.9x
Price/Sales 41.7x

Growth & Margins

Revenue Growth (YoY) +18.2%
Gross Margin +77.3%
Operating Margin -212.7%
Net Margin -252.0%
EPS Growth +18.2%

Financial Health

Cash/Price Ratio +10.5%
Current Ratio 6.4x
Debt/Equity 239.9x
ROE -890.7%
ROA -26.0%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Insmed Inc logo

Insmed Inc (INSM) Company Overview

About Insmed Inc

What They Do

Develops therapies for serious rare diseases.

Business Model

Insmed Incorporated operates as a biopharmaceutical company focusing on the development and commercialization of treatments for serious and rare diseases. The company generates revenue primarily through the sales of its approved therapy ARIKAYCE, while also investing in the research and development of additional products like Brensocatib and Treprostinil Palmitil Inhalation Powder to diversify its portfolio and address various unmet medical needs.

Additional Information

Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed is actively expanding its presence in the United States, Europe, Japan, and other international markets, aiming to improve patient outcomes for those suffering from challenging health conditions.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

912

CEO

Mr. William H. Lewis J.D., M.B.A.

Country

United States

IPO Year

2000

Insmed Inc (INSM) Latest News & Analysis

INSM stock latest news image
Quick Summary

Insmed Incorporated (Nasdaq: INSM) will announce its Q4 and full-year 2024 financial results on February 20, 2025.

Why It Matters

The announcement of Insmed's Q4 and full-year 2024 financial results can significantly impact stock performance and investor sentiment, reflecting the company's growth and operational health.

Source: PRNewsWire
Market Sentiment: Neutral
INSM stock latest news image
Quick Summary

Insmed's brensocatib has received FDA acceptance for its New Drug Application, potentially becoming the first treatment for non-cystic fibrosis bronchiectasis and the first DPP1 inhibitor.

Why It Matters

Approval of brensocatib could position Insmed as a market leader in treating bronchiectasis, potentially driving revenue growth and stock value due to lack of competition.

Source: PRNewsWire
Market Sentiment: Neutral
INSM stock latest news image
Quick Summary

Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 66 new employees, indicating ongoing growth and investment in talent.

Why It Matters

Insmed's inducement awards signal growth and investment in talent, indicating potential expansion and innovation, which can positively influence stock performance and investor confidence.

Source: PRNewsWire
Market Sentiment: Neutral
INSM stock latest news image
Quick Summary

The FDA has accepted INSM's NDA for brensocatib for non-cystic fibrosis bronchiectasis and granted priority review, with a decision expected by August 12, 2025.

Why It Matters

The FDA's priority review of INSM's brensocatib signals potential faster market entry, impacting revenue projections and stock performance ahead of the 2025 decision.

Source: Zacks Investment Research
Market Sentiment: Positive
INSM stock latest news image
Quick Summary

Insmed's Arikayce earned $93.4m in Q3 2023, with full-year guidance of $340m-$360m. Brensocatib received FDA Priority Review, with peak annual revenue projections over $5bn. Market cap: $14.45bn.

Why It Matters

Insmed's strong Q3 revenue from Arikayce and promising FDA review for Brensocatib highlight growth potential, likely driving investor confidence and supporting stock performance.

Source: Seeking Alpha
Market Sentiment: Positive
INSM stock latest news image
Quick Summary

Insmed forecasts 2024 global ARIKAYCE revenues at $363.7M and expects 2025 revenues between $405M-$425M. Key clinical developments include a new drug application and ongoing trials with data expected in 2025-2026.

Why It Matters

Strong revenue growth for ARIKAYCE and upcoming product launches signal positive momentum for Insmed, potentially enhancing investor confidence and stock value.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About INSM Stock

What is Insmed Inc's (INSM) stock forecast for 2025?

Based on our analysis of 21 Wall Street analysts, Insmed Inc (INSM) has a median price target of $90.00. The highest price target is $105.00 and the lowest is $67.26.

Is INSM stock a good investment in 2025?

According to current analyst ratings, INSM has 17 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $78.12. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for INSM stock?

Wall Street analysts predict INSM stock could reach $90.00 in the next 12 months. This represents a 15.2% increase from the current price of $78.12. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Insmed Inc's business model?

Insmed Incorporated operates as a biopharmaceutical company focusing on the development and commercialization of treatments for serious and rare diseases. The company generates revenue primarily through the sales of its approved therapy ARIKAYCE, while also investing in the research and development of additional products like Brensocatib and Treprostinil Palmitil Inhalation Powder to diversify its portfolio and address various unmet medical needs.

What is the highest forecasted price for INSM Insmed Inc?

The highest price target for INSM is $105.00 from Nicole Germino at Truist Securities, which represents a 34.4% increase from the current price of $78.12.

What is the lowest forecasted price for INSM Insmed Inc?

The lowest price target for INSM is $67.26 from at , which represents a -13.9% decrease from the current price of $78.12.

What is the overall INSM consensus from analysts for Insmed Inc?

The overall analyst consensus for INSM is bullish. Out of 21 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $90.00.

How accurate are INSM stock price projections?

Stock price projections, including those for Insmed Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.